Drugs / BO-112
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04777708 | Oct 2021 → Mar 2023 | hepatocellular carcinoma | Jonsson Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT04420975 | Oct 2020 → Jan 2027 expected | dedifferentiated liposarcoma, fibrosarcoma, leiomyosarcoma, malignant peripheral nerve sheath tumor +7 | Jonsson Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02828098 | Jun 2016 → Jul 2020 | cancer | Highlight Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05265650 | Jun 2022 → Mar 2024 | non-small cell lung carcinoma | Clinica Universidad de Navarra, Universidad de Navarra | Unknown | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06422936 | May 2024 → Jun 2026 overdue | basal cell carcinoma | Highlight Therapeutics | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04570332 | Dec 2020 → Oct 2023 | melanoma | Highlight Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT04508140 | Jun 2020 → Dec 2022 | colorectal cancer, esophageal cancer, gastric cancer | Highlight Therapeutics | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BO-112 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04777708 ↗ |
| Known as | Nanoplexed Poly I:C BO-112 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04420975 ↗ |
| Modality | Oligonucleotide (other) | “synthetic, double-stranded RNA” PMID 40577656 ↗ Jun 2025 |
| Route | Other | “intratumorally delivered BO-112” PMID 31046839 ↗ May 2019 |